American Journal of Preventive Medicine publishes first national study of occupational fatalities Although traumatic brain injury (TBI) is one of...
New research out of Michigan State University reveals female athletes and younger athletes take longer to recover from concussions, findings...
Diabetes Drug Could Be a Promising Therapy for Traumatic Brain Injury TAU research finds that existing diabetes medication may ease...
Study Links PTSD to Hidden Head Injuries Suffered in Combat. Even when brain injury is so subtle that it can...
An experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy has been created.
A study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer’s disease, found that a single event of a moderate-to-severe traumatic brain injury (TBI) can disrupt proteins that regulate an enzyme associated with Alzheimer’s. The paper, published in The Journal of Neuroscience, identifies the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain. These results may lead to the development of a drug treatment that targets this mechanism to slow the progression of Alzheimer’s disease.
A new study found soldiers returning from Iraq and Afghanistan with mild TBI have measurable abnormalities in white matter when compared to returning veterans who have not experienced TBI. These abnormalities appear to be related to the severity of the injury and are related to cognitive deficits.
New research into concussions sustained during sports shows damage to the brain can persist for decades after an original or head trauma. The long-term consequences of concussions include memory loss, attention deficits and motor control problems.
A new study finds lasting structural damage to the brain can be caused by a single concussion.
According to three new studies, numerous opportunities exist to improve the outcomes of TBI in older adults.
Researchers evaluate the pathological impact of single incident TBI and mild, repetitive traumatic brain injury, in order to learn which measures need to be taken to identify risk, early incidence and to reduce long term complications associated with TBI.
A new study supports p38α MAPK as a possible clinical target for treating central nervous system disorders associated with uncontrolled brain inflammation, including TBI.
